BRPI0607326A2 - composição de vacina, variante de peptìdeo de survivina, uso da referida composição, kit em partes e medicamento - Google Patents

composição de vacina, variante de peptìdeo de survivina, uso da referida composição, kit em partes e medicamento

Info

Publication number
BRPI0607326A2
BRPI0607326A2 BRPI0607326-3A BRPI0607326A BRPI0607326A2 BR PI0607326 A2 BRPI0607326 A2 BR PI0607326A2 BR PI0607326 A BRPI0607326 A BR PI0607326A BR PI0607326 A2 BRPI0607326 A2 BR PI0607326A2
Authority
BR
Brazil
Prior art keywords
composition
vaccine
kit
parts
medicament
Prior art date
Application number
BRPI0607326-3A
Other languages
English (en)
Inventor
Mads Hald Andersen
Original Assignee
Survac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Survac Aps filed Critical Survac Aps
Publication of BRPI0607326A2 publication Critical patent/BRPI0607326A2/pt
Publication of BRPI0607326B1 publication Critical patent/BRPI0607326B1/pt
Publication of BRPI0607326B8 publication Critical patent/BRPI0607326B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçãO DE VACINA, VARIANTE DE PEPTìDEO DE SURVIVINA, USO DA REFERIDA COMPOSIçãO, KIT EM PARTES E MEDICAMENTO. A presente invenção refere-se a uma vacina terapêutica compreendendo um ou mais fragmentos de polipeptídeo de Survivina. A vacina pode ser usada para o tratamento profilático, de melhora e/ou curativo de, por exemplo, doenças de câncer. A invenção refere-se ainda a métodos de tratamento de combinação.
BRPI0607326A 2005-02-04 2006-02-03 composição de vacina, uso da referida composição e kit em partes BRPI0607326B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200500173 2005-02-04
DKPA200500173 2005-02-04
US65075105P 2005-02-07 2005-02-07
US60/650,751 2005-02-07
PCT/DK2006/000061 WO2006081826A2 (en) 2005-02-04 2006-02-03 Survivin peptide vaccine

Publications (3)

Publication Number Publication Date
BRPI0607326A2 true BRPI0607326A2 (pt) 2009-09-01
BRPI0607326B1 BRPI0607326B1 (pt) 2021-01-19
BRPI0607326B8 BRPI0607326B8 (pt) 2021-05-25

Family

ID=39042995

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607326A BRPI0607326B8 (pt) 2005-02-04 2006-02-03 composição de vacina, uso da referida composição e kit em partes

Country Status (15)

Country Link
US (1) US20110091489A1 (pt)
EP (3) EP1853305B1 (pt)
JP (2) JP2008528643A (pt)
KR (1) KR20070108536A (pt)
CN (3) CN101111260B (pt)
AU (1) AU2006209951B2 (pt)
BR (1) BRPI0607326B8 (pt)
CA (1) CA2593714C (pt)
DK (1) DK1853305T3 (pt)
ES (1) ES2523172T3 (pt)
MX (1) MX2007009219A (pt)
PL (1) PL1853305T3 (pt)
RU (1) RU2396088C2 (pt)
WO (1) WO2006081826A2 (pt)
ZA (1) ZA200705943B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342093B2 (en) 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
EP2155782A2 (en) * 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (en) * 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
EP2254592B1 (en) * 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
NO2280721T3 (pt) 2008-04-17 2018-04-14
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
FR2955776A1 (fr) * 2010-02-01 2011-08-05 Seppic Sa Utilisation d'une huile minerale specifique pour la fabrication d'un nouveau adjuvant
FR2955775B1 (fr) 2010-02-01 2012-05-04 Seppic Sa Adjuvant pour la preparation de compositions vaccinales destinees a la prevention contre les coccidioses
RS62406B1 (sr) 2012-05-16 2021-10-29 Stemline Therapeutics Inc Vakcine protiv kancera sa ciljanim delovanjem na matične ćelije kancera
EP2978450B1 (en) 2013-03-27 2018-09-19 ImmunoVaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
WO2015090572A1 (en) * 2013-12-16 2015-06-25 Merck Patent Gmbh Survivin-directed cancer vaccine therapy
CN107531736B (zh) 2015-01-06 2022-04-15 免疫疫苗科技公司 脂质a模拟物、其制备方法和用途
WO2016146143A1 (en) * 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
CA3005127C (en) 2015-11-18 2023-01-24 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
WO2017147263A1 (en) * 2016-02-23 2017-08-31 National Health Research Institutes Lipidated survivin and the use thereof for prevention and treatment of cancers
PT3429618T (pt) 2016-03-16 2024-04-02 Amal Therapeutics Sa Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina
IL265479B (en) 2016-09-21 2022-09-01 Amal Therapeutics Sa A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy
CN107228894B (zh) * 2017-01-24 2019-03-19 浙江海隆生物科技有限公司 一种油乳剂蛋白亚单位疫苗中蛋白含量和纯度的检测方法及其应用
AU2018226566B2 (en) 2017-03-03 2025-01-23 Treos Bio Limited Population-based immunogenic peptide identification platform
JP6993677B2 (ja) * 2017-11-08 2022-01-13 学校法人日本医科大学 犬におけるがんの予防、がんの治療またはがんの転移の予防のためのがんペプチドワクチン
TWI837109B (zh) * 2017-12-28 2024-04-01 美商磨石生物公司 靶向共有抗原之抗原結合蛋白
MA53543A (fr) * 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
CA3119910A1 (en) * 2018-11-19 2020-05-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
CN115477686B (zh) * 2022-09-22 2024-01-30 北海黑珍珠海洋生物科技有限公司 一种具有美白功效的珍珠贝活性肽及其应用
WO2024186623A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making dried pharmaceutical compositions
WO2024186646A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making lipid adjuvanted compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU679902B2 (en) * 1992-09-30 1997-07-17 Ohio State University Research Foundation, The Vaccines and antigenic conjugates
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
CA2271783C (en) 1996-11-20 2013-04-16 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
EP1294905A1 (en) * 2000-06-26 2003-03-26 SmithKline Beecham Biologics SA Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
WO2002055100A2 (en) * 2000-10-20 2002-07-18 Genetics Institute, Llc Method and composition for inhibition of tumor growth and enhancing an immune response
JP2002365286A (ja) * 2000-11-13 2002-12-18 Kyogo Ito 細胞性免疫検出法およびその医薬への応用
JP4780540B2 (ja) * 2001-03-23 2011-09-28 北海道公立大学法人 札幌医科大学 サバイビン由来癌抗原ペプチド
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20040210035A1 (en) * 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6780121B2 (en) * 2002-09-09 2004-08-24 Paul J. Herber Golf club head construction
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
US7221826B2 (en) * 2002-10-08 2007-05-22 Tdk Corporation Spot-size transformer, method of producing spot-size transformer and waveguide-embedded optical circuit using spot-size transformer
ES2323692T3 (es) * 2002-12-02 2009-07-23 Resistentia Holding Ab Metodos y materiales para tratar afecciones inflamatorias usando un polipeptido que comprende un segmento de aminoacidos c5 autogenicos y un segmento de aminoacidos no autogenicos.
KR101399678B1 (ko) * 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
CA2530184C (en) * 2003-06-27 2015-10-06 Haruo Sugiyama Method of selecting patients suitable for wt1 vaccine
EP2087904B1 (en) * 2003-11-19 2013-08-28 Survac ApS Therapeutic use of peptides derived from Bcl-XL protein in cancer patients

Also Published As

Publication number Publication date
EP1853305B1 (en) 2014-08-20
AU2006209951A1 (en) 2006-08-10
EP1853305A2 (en) 2007-11-14
ZA200705943B (en) 2008-12-31
PL1853305T3 (pl) 2015-02-27
JP5631357B2 (ja) 2014-11-26
WO2006081826A2 (en) 2006-08-10
RU2396088C2 (ru) 2010-08-10
EP2329841A1 (en) 2011-06-08
BRPI0607326B1 (pt) 2021-01-19
MX2007009219A (es) 2008-01-16
RU2007133103A (ru) 2009-03-10
BRPI0607326B8 (pt) 2021-05-25
CN103169958A (zh) 2013-06-26
HK1112367A1 (en) 2008-08-29
JP2008528643A (ja) 2008-07-31
DK1853305T3 (en) 2014-12-01
CN103143004A (zh) 2013-06-12
US20110091489A1 (en) 2011-04-21
CA2593714A1 (en) 2006-08-10
ES2523172T3 (es) 2014-11-21
CA2593714C (en) 2013-09-10
EP2329840A1 (en) 2011-06-08
CN101111260A (zh) 2008-01-23
WO2006081826A3 (en) 2007-02-15
KR20070108536A (ko) 2007-11-12
CN101111260B (zh) 2013-03-20
JP2012149101A (ja) 2012-08-09
AU2006209951B2 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
BRPI0607326B8 (pt) composição de vacina, uso da referida composição e kit em partes
BR112019000598A2 (pt) rna para terapia de câncer
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
CR9348A (es) Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer
BR112012018951B8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112012018947B8 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BRPI0410503B8 (pt) composição tópica e uso da composição
BRPI0513681A (pt) composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer
BR112012012918A8 (pt) Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".
WO2007059979A3 (en) Allergy treatment by epicutaneous allergen administration
BRPI0415755A (pt) antagonistas do receptor b1 de bradiquinina
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
BR112013018365A2 (pt) "peptídeos derivados da lactoferrina humana, uso dos mesmos e composição farmacêutica"
HRP20110724T1 (hr) Smjese koje sadrže peptide mijelinskog bazičnog proteina i njihova medicinska uporaba
BR112019011350A2 (pt) terapia de combinação
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF